Linagliptin NEW

Manufacturer Provide Raw Material Linagliptin Powder CAS 668270-12-0 Linagliptin

Introduction

Product Name: Linagliptin

Other Name :Linagliptin; (R)-8-(3-aminopiperidin-1-yl)-7-(but-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-1H-purine-2,6(3H,7H)-dione

CAS NO:668270-12-0

Purity: 99%min
Appearance:White crystalline powder

Molecular formula: C25H28N8O2

MW:472.54

Melting Point :202 ºC

Boiling Point :661.2±65.0 °C(Predicted)

Density:1.39

Storage :Keep in dark place,Inert atmosphere,Room temperature

Linagliptin (trade names Tradjenta and Trajetna) is an inhibitor of dipeptidyl peptidase-4 (DPP-4) that was approved by the U.S. FDA in May 2011 for the treatment of Type 2 diabetes along with diet and exercise. Linagliptin (BI-1356) has been described as a potent highly selective, slow-off rate and long acting inhibitor of DPP-4.

Application

Linagliptin arose from optimization efforts of xanthine-based DPP-4 inhibitors with the initial lead identified from an HTS campaign. After optimizing the activity of the initial micromolar lead, two issues that needed to be addressed were activity for hERG and muscarinic receptor M1.